Corporate Partners

ASRA Pain Medicine welcomes support from its corporate partners. There are several ways for corporations to be recognized for their support of the organization and its goals. Together, we can make a difference for patients and the education of physicians who serve them. Acceptance of any form of corporate support is independent of ASRA Pain Medicine's policies and programming, and does not constitute endorsement of any company or product.

Apply to become a corporate partner »

or contact Elizabeth Smith, Executive Director at esmith@asra.com.

The purpose of promoting ASRA Pain Medicine Corporate Partnership is to develop and sustain a mutually beneficial relationship between ASRA Pain Medicine and members of industry who have a vested interest in the area of regional anesthesia and pain management. The monies gained by ASRA Pain Medicine from the Corporate Partnership Program provide an additional source of revenue for the Society each year, which is applied toward educational and research endeavors ASRA Pain Medicine wishes to provide for its physician members.

Your best opportunity to partner with ASRA Pain Medicine is through the Corporate Partnership Program. By becoming an ASRA Pain Medicine Corporate Partner, you will help advance the quality of care provided by ASRA Pain Medicine physician member by contributing your voice and support to members' efforts in research, education, treatment, and advocacy. Learn more about the many benefits of becoming an ASRA Pain Medicine Corporate Partner.

Thank You to ASRA Pain Medicine's Corporate Partners:

At Medtronic, we're committed to Innovating for Life by pushing the boundaries of medical technology and changing the way the world treats chronic disease. Medtronic Neuromodulation provides implantable neurostimulation and drug delivery devices to treat intractable pain, movement and neurological disorders. We offer the largest range of Neuromodulation products with exceptional technical services and patient support.

Pacira BioSciences, Inc. is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Pajunk® Medical is a leading manufacturer in regional anesthesia, neurology, pain management, minimally invasive surgery, and biopsy. Pajunk was founded in 1965 by two brothers, Horst and Heinrich Pajunk, who had a vision to bring high quality German engineering to the manufacturing of medical devices. Throughout the years Pajunk became well-known for working closely with clinicians on new innovations, further strengthening the efficacy of their product portfolio. Today, the tradition continues as the next generation of Pajunk’s are dedicated to expanding their innovations to existing and new markets, including interventional and chronic pain.

Pajunk is headquartered in Geisingen, Germany, with subsidiaries in Atlanta (USA) and Newcastle (UK). In the US, Pajunk specializes in regional anesthesia and pain management by offering market-leading solutions for peripheral and continuous nerve blocks, neuraxial procedures and diagnostics, and interventional pain. Learn more at www.pajunkusa.com or www.pajunk.com.

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.

Information on advertising and sponsorship can be found here.